Preclinical data from the TP53-altered prostate cancer line PC3 have demonstrated synergy between veliparib and cytotoxic therapies (10), and those with alterations in ATM, another DNA-damage response gene, have also been reported to respond to PARP inhibitors (11). The gene discussed is TP53; the disease is prostate carcinoma.